

Y.-Y. Hong¹, F.-Y. Yu¹, J.-F. Qu¹, F. Chen^{2*},
and T.-J. Li^{1*}

¹Department of Oral Pathology, Peking University School and Hospital of Stomatology, 22 Zhongguancun Avenue South, Haidian District, Beijing 100081, China; and ²Central Laboratory, Peking University School and Hospital of Stomatology, 22 Zhongguancun Avenue South, Haidian District, Beijing 100081, China; *corresponding authors, litiejun22@vip.sina.com, moleculcf@gmail.com

J Dent Res DOI: 10.1177/0022034514542108

Fibroblasts Regulate Variable Aggressiveness of Syndromic Keratocystic and Non-syndromic Odontogenic Tumors

APPENDIX

Appendix Table 1. Summary of Patient Information

No.	Gender	Age (yrs)	Type	Clinical Manifestation
Patient 1	Female	16	Syndrom	Multiple KCOTs, multiple skin naevi, calcification of falx cerebri, bifid rib
Patient 2	Female	32	Syndrom	Multiple KCOTs, palmar/plantar pits, calcification of falx cerebri, bridged sella, frontal bossing, multiple skin naevi
Patient 3	Female	60	Syndrom	Multiple KCOTs, multiple skin naevi, calcification of falx cerebri, bifid rib, telecanthus
Patient 4	Male	15	Syndrom	Multiple KCOTs, palmar/plantar pits, bifid rib, telecanthus, frontal bossing, cleft lip and palate
Patient 5	Male	45	Syndrom	Multiple KCOTs, palmar/plantar pits, bifid rib, cleft lip and palate
Patient 6	Female	20	Syndrom	Multiple KCOTs, bifid rib, multiple skin naevi
Patient 7	Male	30	Syndrom	Multiple KCOTs, bifid rib, calcification of falx cerebri
Patient 8	Male	17	Syndrom	Multiple KCOTs, bifid rib, calcification of falx cerebri
Patient 9	Male	18	Non-syndrom	Sporadic KCOT
Patient 10	Male	32	Non-syndrom	Sporadic KCOT
Patient 11	Male	31	Non-syndrom	Sporadic KCOT
Patient 12	Male	25	Non-syndrom	Sporadic KCOT
Patient 13	Male	26	Non-syndrom	Sporadic KCOT
Patient 14	Female	59	Non-syndrom	Sporadic KCOT
Patient 15	Female	49	Non-syndrom	Sporadic KCOT
Patient 16	Female	56	Non-syndrom	Sporadic KCOT

Ages were recorded at the time of surgery. The clinical manifestations were according to the history health check results from doctors.

Appendix Table 2. Primers for Gene Expression Assay

Genes	Forward Primers (5'-3')	Reverse Primers (5'-3')
GAPDH (RT-PCT)	ATGCCAGTGAGCTTCCCGTTCAGC	TGGTATCGTGGAAGGACTCATGAC
PPAR γ 2 (RT-PCT)	GGGGTGATGTGTTGAAGTTG	CAGGAAAGACAACAGACAAATCA
LPL (RT-PCT)	GAAGGAGTAGGTCTTATTTGTGGAA	GTGGCCGAGAGTGAGAACAT
Runx2 (RT-PCR)	CCGCACGACAACCGCACCAT	CGCTCCGGCCCAAAATCTC
OCN (RT-PCR)	CCCAAAGGCTTCTTCTTG	CTGGTAGTTGTTGTGAGC
GAPDH (Real-time PCR)	ACAACCTTTGGTATCGTGGAAGG	GCCATCACGCCACAGTTTC
Runx2 (Real-time PCR)	AGTGGACGAGGCAAGAGTTTCA	GGGTTCCCGAGGTCCATCTA
COL1A1 (Real-time PCR)	AGACACTGGTGCTAAGGGAGAG	GACCAGCAACACCATCTGCG
OCN (Real-time PCR)	CCTGAAAGCCGATGTGGT	AGGGCAGCGAGGTAGTGA
OPN (Real-time PCR)	GGCCGAGGTGATAGTGTGGTT	CTCCTCGCTTCCATGTGTGA
IL-1 α (Real-time PCR)	AGATGGCCAAAGTTCCTGAC	CCCAGTATGAGTGGCATAA
Cox2 (Real-time PCR)	CCAGTATAAGTGCGATTGTACCC	TCAAAAATCCGGTGTGAGCA
RANKL (Real-time PCR)	AGATCGCTCCTCCATGTACCA	GCCTTGCCTGTATCACAACCT
OPG (Real-time PCR)	CCTCCAAGCCCCTGAAGGTT	CCTGGGTGGTCCACTTAATGG

Appendix Table 3. mRNA Expression Levels of Osteoblast-specific Genes

Genes	Day 3 (NS-KCOT vs. S-KCOT)	Day 7 (NS-KCOT vs. S-KCOT)
Runx2	2.33-fold (1.43 \pm 0.40 vs. 0.61 \pm 0.13)	1.42-fold (1.32 \pm 0.13 vs. 0.93 \pm 0.15)
COL1A1	3.11-fold (1.76 \pm 0.47 vs. 0.57 \pm 0.22)	2.72-fold (2.08 \pm 0.13 vs. 0.77 \pm 0.49)
OCN	5.99-fold (2.86 \pm 3.03 vs. 0.48 \pm 0.21)	4.92-fold (4.97 \pm 5.10 vs. 1.01 \pm 0.19)
OPN	3.76-fold (1.49 \pm 0.54 vs. 0.40 \pm 0.20)	8.47-fold (6.42 \pm 4.96 vs. 0.76 \pm 0.32)